Russia's FSB says minor detained over park attack threat after US tip-off Reuters
Why SLBT Stock dropped -3.31% Today — RQD Quant Desk Flash
SL Science Holding Limited (SLBT) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is SLBT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-01, SL Science Holding Limited (NASDAQ: SLBT) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $1.17 (-3.31% 1D, market cap $656.1M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, SLBT ranks #409 in composite RQD confidence.
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does SLBT compare to AURA and CADL in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SLBT carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, AURA (Aura Biosciences Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $652.8M) and CADL (Candel Therapeutics Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $661.9M). Among the 5-stock peer group, SLBT leads on earnings multiple (N/A) while AURA leads on capital efficiency (-35.0% ROIC).
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for SLBT?
▼
Per SLBT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002070534), SL Science Holding Limited generated $0 in revenue, $0 in net income, and $0 in free cash flow against $11.8K in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC XBRL FY 2025 (10-K): 0.5% FCF Margin ($18.4M FCF) & 52% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)
⚔️ Adversarial Opposing Case: What Could Spark a SLBT Turnaround Squeeze
While SLBT currently carries a cautious 47/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.89) and Max Pain ($1.23) forces dealer call-delta covering toward $15.23.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Why SLBT Stock dropped -3.31% Today — RQD Quant Desk Flash
SL Science Holding Limited (SLBT) dropped -3.31% to $1.17, trading at 2% of its 52-week range ($1.02 – $14.5). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($1.02 – $14.5) with RSI-14 at 29.2 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.17 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $18.4M annual free cash flow.
Oil slips more than 1% as talks continue on ending Iran war Reuters
Nine people dead in Learjet crash in south Florida, officials say Reuters
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
The market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Haley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
Israeli strikes kill eight people in Gaza - medics say Reuters
Iran, Qatari mediators hold third day of talks to end US-Iran war Reuters
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SLBT)
- ✓Walkthrough of SLBT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
SLBT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on SLBT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for SLBT. Explore sector supply chains on /butterfly.
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SLBT)
1. Head-to-Head Health Care Peer Comparison (SLBT vs. AURA, CADL, DBVT, IAM)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, SL Science Holding Limited (SLBT) ranks #409 by composite RQD confidence (47/100, grade D) and #409 by equity capitalization ($656.1M). Within this direct 5-issuer industry benchmark cohort, SLBT leads on earnings valuation at N/A trailing P/E, while AURA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. IAM currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with SLBT at 47/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SLBT
ACTIVE
SL Science Holding Limited | D | 47/100 | — | — | — | -3.31% | $656.1M | Benchmark Subject |
| AURA Aura Biosciences Inc. | D- | 40/100 | — | — | -35.0% | -1.64% | $652.8M | /aura-vs-slbt → |
| CADL Candel Therapeutics Inc. | D- | 38/100 | — | — | -35.0% | -0.23% | $661.9M | /cadl-vs-slbt → |
| DBVT DBV Technologies S.A. | E | 26/100 | — | — | -35.0% | -3.38% | $647.0M | /dbvt-vs-slbt → |
| IAM Iambic Therapeutics Inc. | D | 50/100 | — | — | — | -3.38% | $676.9M | /iam-vs-slbt → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002070534In its most recent audited fiscal period (FY2025, filed 2025-12-31), SL Science Holding Limited (SLBT) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, SLBT closed FY2025 with $11.8K in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | $0 | — | — | $11.8K | — |
3. SLBT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs SLBT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, SL Science Holding Limited (NASDAQ: SLBT) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $1.17 (-3.31% 1D, market cap $656.1M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, SLBT ranks #409 in composite RQD confidence.
How does SLBT compare to AURA and CADL in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SLBT carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, AURA (Aura Biosciences Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $652.8M) and CADL (Candel Therapeutics Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $661.9M). Among the 5-stock peer group, SLBT leads on earnings multiple (N/A) while AURA leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for SLBT?
Per SLBT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002070534), SL Science Holding Limited generated $0 in revenue, $0 in net income, and $0 in free cash flow against $11.8K in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is SLBT trading relative to its 50-day, 200-day, and 52-week technical levels?
SLBT last traded at $1.17 (-3.31% on volume of 24,563 shares), positioning the stock -38.10% below its 50-day simple moving average ($1.89) and -80.79% below its 200-day simple moving average ($6.09). Across its 52-week range of $1.02 to $14.50, SLBT sits at the 1.1% percentile with a 14-day RSI of 29.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.02 to $1.32).
SLBT Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is SLBT stock moving today?
Why SLBT Stock dropped -3.31% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.